N-Phenylacetyl-L-prolylglycine ethyl ester
•Last Updated: February 23 2023
N-phenylacetyl-L-prolylglycine ethyl ester (brand name: Noopept), a Nootropic molecule similar to Piracetam that may alleviate cognitive decline.
N-Phenylacetyl-L-prolylglycine ethyl ester is most often used for
Last Updated: February 23 2023
N-phenylacetyl-L-prolylglycine ethyl ester, or Noopept, is a synthetic pharmaceutical designed by a Russian pharmaceutical company. It is sometimes called a nootropic, based on preliminary evidence that it has neuroprotective and cognitive enhancing properties.[45][46][47] Noopept was designed using the structure of piracetam, another nootropic, as a starting point.[48]
Noopept may be beneficial for brain health, but this claim is based almost exclusively on studies in which Noopept was administered (often via injection) to rodents with brain damage caused by toxin injection, oxygen deprivation, and other methods.[49][50][51][52][ One of the only controlled trials involving humans found that Noopept supplementation improved cognitive function in a small group of people with mild cognitive impairment (MCI) resulting from a stroke.[53] These findings have not yet been independently replicated.
Sleep disturbances, irritability, and increases in blood pressure have been reported in people taking Noopept.[54][53] It should be stressed that there is not much research evaluating the safety of Noopept.
Given its similarities to other nootropics like piracetam and ampakines, Noopept may also cause dizziness, headaches, gastrointestinal symptoms, and impairments in memory, although these effects are speculative.[55]
Noopept’s mechanism of action is uncertain, but several possibilities have been proposed. In particular, it may increase levels of brain-derived neurotrophic factor (BDNF), a protein that helps establish neural connections and neurotransmission in the brain.[56] Noopept may also activate or modulate neurotransmitter receptors involved in learning and cognitive function, including certain glutamatergic and cholinergic receptors.[57][58][47]
Note that N-Phenylacetyl-L-prolylglycine ethyl ester is also known as:
- Noopeptide
- Ноопепт
- GVS-111
- Noopept
N-Phenylacetyl-L-prolylglycine ethyl ester should not be confused with:
- Piracetam (Basic racetam
- but different molecule)
To supplement Noopept, take 10 – 30 mg, once a day, for up to 56 days at a time. More research is needed to determine the optimal human dose for Noopept.
What works and what doesn't?
Unlock the full potential of Examine
2.^Gudasheva TA, Konstantinopol'skii MA, Ostrovskaya RU, Seredenin SBAnxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze testBull Exp Biol Med.(2001 May)
3.^Neznamov GG, Teleshova ESComparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic originNeurosci Behav Physiol.(2009 Mar)
4.^Ostrovskaia RU, Gudasheva TA, Voronina TA, Seredenin SBThe original novel nootropic and neuroprotective agent noopeptEksp Klin Farmakol.(2002 Sep-Oct)
5.^Jia X, Gharibyan AL, Öhman A, Liu Y, Olofsson A, Morozova-Roche LANeuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicityJ Mol Biol.(2011 Dec 16)
6.^Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SBThe major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycineEur J Drug Metab Pharmacokinet.(1997 Jul-Sep)
7.^Boiko SS, Ostrovskaya RU, Zherdev VP, Korotkov SA, Gudasheva TA, Voronina TA, Seredenin SBPharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administrationBull Exp Biol Med.(2000 Apr)
8.^Vorobyov V, Kaptsov V, Kovalev G, Sengpiel FEffects of nootropics on the EEG in conscious rats and their modification by glutamatergic inhibitorsBrain Res Bull.(2011 May 30)
10.^Ostrovskaya RU, Mirsoev TK, Romanova GA, Gudasheva TA, Kravchenko EV, Trofimov CC, Voronina TA, Seredenin SBProline-containing dipeptide GVS-111 retains nootropic activity after oral administrationBull Exp Biol Med.(2001 Oct)
11.^Ostrovskaya RU, Romanova GA, Barskov IV, Shanina EV, Gudasheva TA, Victorov IV, Voronina TA, Seredenin SBMemory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke modelBehav Pharmacol.(1999 Sep)
12.^Ostrovskaya RU, Gudasheva TA, Zaplina AP, Vahitova JV, Salimgareeva MH, Jamidanov RS, Seredenin SBNoopept stimulates the expression of NGF and BDNF in rat hippocampusBull Exp Biol Med.(2008 Sep)
13.^Radionova KS, Belnik AP, Ostrovskaya RUOriginal nootropic drug noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockadeBull Exp Biol Med.(2008 Jul)
14.^Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LDFrom acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learningLearn Mem.(2002 Sep-Oct)
15.^Bel'nik AP, Ostrovskaya RU, Poletaeva IIGenotype-dependent characteristics of behavior in mice in cognitive tests. The effects of NoopeptNeurosci Behav Physiol.(2009 Jan)
16.^Upchurch M, Wehner JMInheritance of spatial learning ability in inbred mice: a classical genetic analysisBehav Neurosci.(1989 Dec)
17.^Passino E, Middei S, Restivo L, Bertaina-Anglade V, Ammassari-Teule MGenetic approach to variability of memory systems: analysis of place vs. response learning and fos-related expression in hippocampal and striatal areas of C57BL/6 and DBA/2 miceHippocampus.(2002)
18.^Schwegler H, Crusio WE, Lipp HP, Heimrich BWater-maze learning in the mouse correlates with variation in hippocampal morphologyBehav Genet.(1988 Mar)
19.^Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RD, Gudasheva TA, Samokhin AN, Seredinin SB, Noppe W, Sherstnev VV, Morozova-Roche LAThe nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease modelJ Psychopharmacol.(2007 Aug)
20.^Romanova GA, Mirzoev TK, Barskov IV, Victorov IV, Gudasheva TA, Ostrovskaya RUAntiamnesic effect of acyl-prolyl-containing dipeptide (GVS-111) in compression-induced damage to frontal cortexBull Exp Biol Med.(2000 Sep)
21.^Antiamnesic effect of acyl-prolyl-containing dipeptide (GVS-111) in compression-induced damage to frontal cortex
22.^Andreeva NA, Stel'mashuk EV, Isaev NK, Ostrovskaya RU, Gudasheva TA, Viktorov IVNeuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stressBull Exp Biol Med.(2000 Oct)
23.^Zarubina IV, Shabanov PDNoopept reduces the postischemic functional and metabolic disorders in the brain of rats with different sensitivity to hypoxiaBull Exp Biol Med.(2009 Mar)
24.^Pelsman A, Hoyo-Vadillo C, Gudasheva TA, Seredenin SB, Ostrovskaya RU, Busciglio JGVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neuronsInt J Dev Neurosci.(2003 May)
25.^Belnik AP, Ostrovskaya RU, Poletaeva IIDipeptide preparation Noopept prevents scopolamine-induced deficit of spatial memory in BALB/c miceBull Exp Biol Med.(2007 Apr)
26.^Romanova GA, Shakova FM, Gudasheva TA, Ostrovskaya RUImpairment of learning and memory after photothrombosis of the prefrontal cortex in rat brain: effects of NoopeptBull Exp Biol Med.(2002 Dec)
27.^Romanova GA, Shakova FM, Kovaleva OI, Pivovarov VV, Khlebnikova NN, Karganov MYRelationship between changes in rat behavior and integral biochemical indexes determined by laser correlation spectroscopy after photothrombosis of the prefrontal cortexBull Exp Biol Med.(2004 Feb)
28.^Ostrovskaya RU, Romanova GA, Trofimov SS, Gudasheva TA, Voronina TA, Halikas JA, Seredenin SBThe novel substituted acylproline-containing dipeptide, GVS-111, promotes the restoration of learning and memory impaired by bilateral frontal lobectomy in ratsBehav Pharmacol.(1997 Jun)
29.^Trofimov SS, Voronina TA, Guzevatykh LSEarly postnatal effects of noopept and piracetam on declarative and procedural memory of adult male and female ratsBull Exp Biol Med.(2005 Jun)
30.^Kondratenko RV, Derevyagin VI, Skrebitsky VGNovel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cellsNeurosci Lett.(2010 May 31)
31.^Fuxe K, Köhler C, Agnati LF, Andersson K, Ogren SO, Eneroth P, Pérez de la Mora M, Karobath M, Krogsgaard-Larsen PGABA and benzodiazepine receptors. Studies on their localization in the hippocampus and their interaction with central dopamine neurons in the rat brainAdv Biochem Psychopharmacol.(1981)
32.^Bertoglio LJ, Joca SR, Guimarães FSFurther evidence that anxiety and memory are regionally dissociated within the hippocampusBehav Brain Res.(2006 Nov 25)
33.^Uyanaev AA, Fisenko VP, Khitrov NKEffect of noopept and afobazole on the development of neurosis of learned helplessness in ratsBull Exp Biol Med.(2003 Aug)
34.^Uyanaev AA, Fisenko VPStudies of long-term noopept and afobazol treatment in rats with learned helplessness neurosisBull Exp Biol Med.(2006 Aug)
35.^Uversky VNAlpha-synuclein misfolding and neurodegenerative diseasesCurr Protein Pept Sci.(2008 Oct)
36.^Zamotin V, Gharibyan A, Gibanova NV, Lavrikova MA, Dolgikh DA, Kirpichnikov MP, Kostanyan IA, Morozova-Roche LACytotoxicity of albebetin oligomers depends on cross-beta-sheet formationFEBS Lett.(2006 May 1)
37.^Malisauskas M, Ostman J, Darinskas A, Zamotin V, Liutkevicius E, Lundgren E, Morozova-Roche LADoes the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicityJ Biol Chem.(2005 Feb 25)
38.^Xue WF, Hellewell AL, Hewitt EW, Radford SEFibril fragmentation in amyloid assembly and cytotoxicity: when size mattersPrion.(2010 Jan-Mar)
39.^Ostrovskaya RU, Belnik AP, Storozheva ZINoopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats)Bull Exp Biol Med.(2008 Jul)
40.^Lutsenko VK, Vukolova MN, Gudasheva TACyclopropyl glycine and proline-containing preparation noopept evoke two types of membrane potential responses in synaptoneurosomesBull Exp Biol Med.(2003 Jun)
41.^Solntseva EI, Bukanova JV, Ostrovskaya RU, Gudasheva TA, Voronina TA, Skrebitsky VGThe effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channelsGen Pharmacol.(1997 Jul)
42.^Bukanova JV, Solntseva EI, Skrebitsky VGSelective suppression of the slow-inactivating potassium currents by nootropics in molluscan neuronsInt J Neuropsychopharmacol.(2002 Sep)
43.^Kovalenko LP, Shipaeva EV, Alekseeva SV, Pronin AV, Durnev AD, Gudasheva TA, Ostrovskaja RU, Seredenin SBImmunopharmacological properties of noopeptBull Exp Biol Med.(2007 Jul)
44.^Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, Ruscher K, Victorov IV, Priller J, Dirnagl U, Volk HD, Meisel AStroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulationJ Exp Med.(2003 Sep 1)